PTV56 for HPV Positive Oropharynx Cancer

Phase-Based Progress Estimates
Icahn School of Medicine at Mount Sinai, New York, NYHPV Positive Oropharynx CancerPTV56 - Radiation
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new, lower-dose treatment for HPV+ oropharynx cancer. They want to see if it's effective and if there are any side effects. They also want to find out which patients would benefit most from this treatment.

Eligible Conditions
  • HPV Positive Oropharynx Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: 5 years

3 years
Progression Free Survival (PFS)
5 years
Acute Toxicity
Local-regional control (LRC)
Long Term Toxicity
Overall Survival (OS)
Progression Free Survival

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Reduced Dose Radiation
1 of 1

Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: PTV56 · No Placebo Group · N/A

Reduced Dose RadiationExperimental Group · 2 Interventions: PTV56, PTV50.4 · Intervention Types: Radiation, Radiation

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

Icahn School of Medicine at Mount SinaiLead Sponsor
789 Previous Clinical Trials
484,472 Total Patients Enrolled
Marshall Posner, MDPrincipal Investigator - Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital
Medical School - Tufts University, Doctor of Medicine
Boston Medical Center, Residency in Internal Medicine
6 Previous Clinical Trials
710 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 12 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Is it possible for interested participants to join this research endeavor?

"As evidenced by the site, this medical trial is still open for enrollment. Initially posted on April 25th 2016 and most recently revised August 23rd 2022, it seeks to recruit new participants." - Anonymous Online Contributor

Unverified Answer

What is the accepted patient capacity for this clinical examination?

"Affirmative. data reveals that recruitment for this clinical trial was launched on April 25th 2016 and the details were most recently amended on August 23rd 2022. 50 participants are being sought at a single site." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.